Table 1 Demographic and histopathological distrubition of the patients
Age, year, mean ± SD, range | 49.55 ± 19.06 (16–78) |
Gender: n(%) | |
Male | 10 (%50) |
Female | 10 (%50) |
Primary/secondary case: n(%) | |
Primary | 6 (%30) |
Secondary | 14 (%70) |
Location: n(%) | |
Upper limb | 6 (%30) |
Lower limb | 14 (%70) |
Lateralization: n(%) | |
Left | 11 (%55) |
Right | 9 (%45) |
Metastatic node status: n(%) | |
Absent | 4 (%20) |
Present | 16 (%80) |
Metastatic node, number, mean ± SD, range | 1.51 ± 1.04 (0–6) |
Pre-perfusion mSIS groups: n(%) | |
mSIS 0 | 8 (%40) |
mSIS 1 | 6 (%30) |
mSIS 2 | 6 (%30) |
Post-perfusion mSIS groups: n(%) | |
mSIS 0 | 1 (%5) |
mSIS 1 | 5 (%25) |
mSIS 2 | 14 (%70) |
Clavien-Dindo classification, n(%) | |
Grade I | 12 (%60) |
Grade II | 3 (%15) |
Grade III | 2 (%10) |
Grade IV | 2 (%10) |
Grade V | 1 (%5) |
Wieberdink toxicity score, n(%) | |
Grade I | 3 (%15) |
Grade II | 14 (%70) |
Grade III | 3 (%15) |
Alpha fetoprotein, ng/mL, mean ± SD, range | 3.09 ± 2 (0.92–8.22) |
Carcinoembryonic antigen, ng/mL, mean ± SD, range | 1.51 ± 1.04 (0.16–3.63) |
Lenght of hospital stay, day, mean ± SD, range | 5.10 ± 1.51 (3–8) |
Early mortality | |
Absent | 18 (%90) |
Present | 2 (%10) |
- before discharge (due to pulmonary embolism) | 1 |
- after discharge | 1 |
Follow-up time, month, mean ± SD, range | 20.47 ± 21.87 (0–82.3) |
Survive | |
Live | 6 (%30) |
Death | 14 (%70) |